Advancing a First-in-Class SSTR5 Agonist Antibody for Post-Bariatric Hypoglycemia
2:00 pm - Thursday 4th March 2027
- Progressing Confo’s lead SSTR5 agonist antibody from discovery through candidate nomination and IND-enabling studies
- Demonstrating how selective GPCR agonist antibodies can restore glycemic control in post-bariatric hypoglycemia through targeted modulation of insulin and incretin signaling
- Sharing scientific and translational learnings from advancing one of the field’s most advanced GPCR agonist antibody programs toward clinical development
